ClinicalTrialsFinder

Blasts Under 20 Percent of Bone Marrow Nucleated Cells Clinical Trials in Palo Alto, California

1 recruitingPalo Alto, California

Showing 1–1 of 1 trials

Recruiting
Phase 2

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Blasts More Than 5 Percent of Bone Marrow Nucleated CellsBCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White Cells+2 more
William Shomali10 enrolled4 locationsNCT03801434